TICKERNOMICS Sign up
Last Update: 2024-03-28 02:09:39
EXACT SCIENCES CORP ( EXAS ) https://www.exactsciences.com
65.24USD
Sector:
Healthcare
Industry:
Diagnostics & Research
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-1.58%
EXAS
SPY
32.74%
-48.22%
EXAS
SPY
92.93%
-24.68%
EXAS
SPY
224.41%
EXAS
407.31%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
11244.58
11295.23
1.85
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-39.86
4.67
3.58
-0.03
0.00
-231.30
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
1.09
73.18
-1.97
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.1936
0.50
0.47
1.32
Other Earnings and Cash Flow Stats:
EXACT SCIENCES CORP ( EXAS ) Net Income TTM ($MM) is -349.86
EXACT SCIENCES CORP ( EXAS ) Operating Income TTM ($MM) is -317.73
EXACT SCIENCES CORP ( EXAS ) Owners' Earnings Annual ($MM) is 149.32
EXACT SCIENCES CORP ( EXAS ) Current Price to Owners' Earnings ratio is 79.24
EXACT SCIENCES CORP ( EXAS ) EBITDA TTM ($MM) is -202.20
EXACT SCIENCES CORP ( EXAS ) EBITDA Margin is -1.97%
Capital Allocation:
EXACT SCIENCES CORP ( EXAS ) has paid 0.00 dividends per share and bought back -5.01318 million shares in the past 12 months
EXACT SCIENCES CORP ( EXAS ) has reduced its debt by 2234.788 million USD in the last 12 months
Capital Structure:
EXACT SCIENCES CORP ( EXAS ) Interest-bearing Debt ($MM) as of last quarter is 190
EXACT SCIENCES CORP ( EXAS ) Annual Working Capital Investments ($MM) are -2137
EXACT SCIENCES CORP ( EXAS ) Book Value ($MM) as of last quarter is 3145
EXACT SCIENCES CORP ( EXAS ) Debt/Capital as of last quarter is 6%
Other Balance Sheet Stats:
EXACT SCIENCES CORP ( EXAS ) has 605 million in cash on hand as of last quarter
EXACT SCIENCES CORP ( EXAS ) has 514 million of liabilities due within 12 months, and long term debt 2362 as of last quarter
EXACT SCIENCES CORP ( EXAS ) has 181 common shares outstanding as of last quarter
EXACT SCIENCES CORP ( EXAS ) has 0 million USD of preferred stock value
Academic Scores:
EXACT SCIENCES CORP ( EXAS ) Altman Z-Score is 1.72 as of last quarter
EXACT SCIENCES CORP ( EXAS ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
EXACT SCIENCES CORP ( EXAS ) largest shareholder is Allspring Global Investments Holdings, LLC owning 1858380 shares at 121.24 ($MM) value
Daniel J Levangie(an insider) Sold 5000 shares of EXACT SCIENCES CORP ( EXAS ) for the amount of $287500.00 on 2024-03-01
0.93% of EXACT SCIENCES CORP ( EXAS ) is held by insiders, and 88.75% is held by institutions
EXACT SCIENCES CORP ( EXAS ) went public on 2001-02-01
Other EXACT SCIENCES CORP ( EXAS ) financial metrics:
FCF:-174.80
Unlevered Free Cash Flow:2201.74
EPS:0.02
Operating Margin:1.09
Gross Profit Margin:73.18
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:0.10
Beta:1.32
Buffet's Owners Earnings:149.32
Price to Owner's Earnings:79.24
About EXACT SCIENCES CORP ( EXAS ) :
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.